MX2023003008A - Vacuna de multiples epitopos para el tratamiento de la enfermedad de alzheimer. - Google Patents

Vacuna de multiples epitopos para el tratamiento de la enfermedad de alzheimer.

Info

Publication number
MX2023003008A
MX2023003008A MX2023003008A MX2023003008A MX2023003008A MX 2023003008 A MX2023003008 A MX 2023003008A MX 2023003008 A MX2023003008 A MX 2023003008A MX 2023003008 A MX2023003008 A MX 2023003008A MX 2023003008 A MX2023003008 A MX 2023003008A
Authority
MX
Mexico
Prior art keywords
synuclein
peptide
alpha
amyloid
beta
Prior art date
Application number
MX2023003008A
Other languages
English (en)
Spanish (es)
Inventor
Robin Barbour
Wagner Zago
Gene Kinney
Original Assignee
Othair Prothena Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Othair Prothena Ltd filed Critical Othair Prothena Ltd
Publication of MX2023003008A publication Critical patent/MX2023003008A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2023003008A 2020-09-18 2021-08-06 Vacuna de multiples epitopos para el tratamiento de la enfermedad de alzheimer. MX2023003008A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063080619P 2020-09-18 2020-09-18
PCT/US2021/045058 WO2022060488A1 (en) 2020-09-18 2021-08-06 Multiepitope vaccine for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2023003008A true MX2023003008A (es) 2023-04-10

Family

ID=80777125

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003008A MX2023003008A (es) 2020-09-18 2021-08-06 Vacuna de multiples epitopos para el tratamiento de la enfermedad de alzheimer.

Country Status (12)

Country Link
US (1) US20230355729A1 (enExample)
EP (1) EP4213941A4 (enExample)
JP (1) JP2023541670A (enExample)
KR (1) KR20230087499A (enExample)
CN (1) CN116438191A (enExample)
AR (1) AR123187A1 (enExample)
AU (1) AU2021345483A1 (enExample)
CA (1) CA3192387A1 (enExample)
IL (1) IL301262A (enExample)
MX (1) MX2023003008A (enExample)
TW (1) TW202227464A (enExample)
WO (1) WO2022060488A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物
MX2024010450A (es) 2022-02-28 2024-09-18 Tridem Bioscience Gmbh & Co Kg Conjugado que consiste de o que comprende al menos un beta-glucano o un manano.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014031697A2 (en) * 2012-08-21 2014-02-27 The Institute Of Molecular Medicine COMPOSITIONS AND METHODS RELATED TO DISEASES ASSOCIATED WITH DEPOSITS OF AMYLOID, TAU, AND α-SYNUCLEIN
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
WO2015155694A1 (en) * 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
AU2016243922A1 (en) * 2015-04-01 2017-11-02 The Scripps Research Institute Methods and compositions related to GPCR agonist polypeptides
JP2023507949A (ja) * 2019-12-30 2023-02-28 スマート リキッド クリスタル テクノロジーズ カンパニー リミテッド 感熱発色型液晶マイクロカプセル及びその製造方法、並びに感熱発色型容器
AU2021276401A1 (en) * 2020-05-19 2022-12-15 Othair Prothena Limited Multi-epitope vaccine for the treatment of Alzheimer's disease
EP4192497A4 (en) * 2020-08-07 2024-08-21 Othair Prothena Limited MULTI-EPITOPIC VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Also Published As

Publication number Publication date
CN116438191A (zh) 2023-07-14
EP4213941A4 (en) 2024-09-25
AR123187A1 (es) 2022-11-09
KR20230087499A (ko) 2023-06-16
JP2023541670A (ja) 2023-10-03
WO2022060488A1 (en) 2022-03-24
AU2021345483A1 (en) 2023-04-13
US20230355729A1 (en) 2023-11-09
IL301262A (en) 2023-05-01
CA3192387A1 (en) 2022-03-24
EP4213941A1 (en) 2023-07-26
TW202227464A (zh) 2022-07-16

Similar Documents

Publication Publication Date Title
PH12022553234A1 (en) Multi-epitope vaccine for the treatment of alzheimer`s disease
MX2023003008A (es) Vacuna de multiples epitopos para el tratamiento de la enfermedad de alzheimer.
MX2023003009A (es) Vacuna de beta-amiloide para el tratamiento de la enfermedad de alzheimer.
MX2023001503A (es) Vacuna de multiples epitopos para tratamiento de la enfermedad de alzheimer.
MX2023001501A (es) Vacuna tau para tratamiento de enfermedad de alzheimer.
AR024074A1 (es) FRAGMENTO ABETA UNIDO A UN PÉPTIDO PORTADOR PARA PREVENIR O TRATAR ENFERMEDADES ASOCIADAS CON DEPoSITOS AMILOIDES DE ABETA, COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN, Y SU USO EN LA PREPARACION DE MEDICAMENTOS.
ATE535252T1 (de) Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit
MX384227B (es) Anticuerpos y fragmentos de unión a antígenos para usarse en el tratamiento y la profilaxis de amiloidosis.
MX2020005700A (es) Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
MX2023003007A (es) Vacuna de sinucleina alfa para el tratamiento de sinucleinopatias.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
Goepfert et al. Soft-tissue sarcoma of the head and neck after puberty: Treatment by surgery and postoperative radiation therapy
MX2021001985A (es) Metodos agnosticos de conteo de plaquetas para tratar la mielofibrosis.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
CN108670969A (zh) 一种治疗骨髓造血功能障碍的药物
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
EA202290027A1 (ru) Способы и композиции для улучшения результатов лечения пациентов с раком
PE20200889A1 (es) METODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNF(alfa)
MX2022014275A (es) Uso de inhibidores del factor d del complemento solos o junto con anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna.
AR122126A1 (es) Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer
MX2022012252A (es) Metodos para tratar la enfermedad de alzheimer.
Epifanova et al. HP-09-006 first results of platelet-rich plasma and low intensity extracorporeal shockwave combined therapy for erectile dysfunction
Tasneem et al. To compare the results of primary closure of pilonidal sinus with or without redivac drain.